Ian Mortimer Receives the 2026 Bloom Burton Award (opens in a new tab)
Bloom Burton honoured Xenon Pharmaceuticals' CEO for a year that included phase 3 results, an FDA filing and a record Canadian biotech equity raise.
Canadian Investment Bank
Toronto healthcare-only investment dealer covering capital raising, M&A, equity research and trading for life sciences companies.
Bloom Burton & Co. is a Toronto investment dealer focused only on healthcare, co-founded in 2008 by Brian Bloom and Jolyon Burton. It raises capital, advises on M&A and strategy, publishes equity research on Canadian healthcare companies, runs institutional sales and trading, and occasionally co-founds companies, covering biotech, pharma, medical devices, diagnostics, healthcare services and IT, and animal health. It is a fixture of the Canadian life sciences ecosystem through its annual Healthcare Investor Conference and the Bloom Burton Award. Many of its team members hold science PhDs or MDs, and it hires investment banking analysts and research associates in Toronto.
7 interview reports0 open roles11 deals5 people30 sources
Seed, private and public financings for healthcare companies, including lead-agent and lead-manager roles on cross-border offerings.
Helps clients conceive, structure and execute M&A, for example as exclusive advisor on the sale of private Canadian pharma companies.
Research on key Canadian healthcare companies, tracking clinical, commercial and competitive developments.
Specialized execution for institutional investors in healthcare.
Commercialization strategy advice, and in select cases co-founding companies with entrepreneurs and researchers instead of charging fees.
| Toronto | ON | headquarters |
Powered by
From the inside
Reasons that work in interviews
3 reasons for Bloom Burton & Co.
Healthcare and life sciences only, which almost nothing else in Canada is.
Research, banking and investing sit together, so you see a company from three angles.
The annual healthcare summit makes the firm a convening point for the sector rather than just a participant.
Unlock the full insights for Bloom Burton & Co.: every round, the topics tested and what candidates experienced
Interview prep
Each row is a start season; the bars are when you apply. The track starts this month, so how far right a bar sits is how far off it is.
Winter 2027
Apply now
Bloom Burton & Co. works as one generalist team: bankers staff deals across these sectors rather than joining a group, so there is no group to pick when you apply. Healthcare-only Toronto dealer; its services span biotech, pharma, medtech, diagnostics, healthcare services and healthcare IT, organised by service line rather than sub-sector teams.
Raising Capital & FinancingMergers & Acquisition AdvisoryStrategic AdvisoryCompany Creation
Co-founder, Chairman and Chief Executive Officer
Leadership
Co-founded Bloom Burton in 2008 and raises capital for healthcare companies through relationships with specialist international investors. Before that he spent six years in healthcare and biotech institutional sales and research at Dundee Securities, and started his career at New York firms SCO Financial Group and Molecular Securities. Holds an Honours BSc in Biochemistry from McMaster and sits on the boards of Satellos Bioscience and Appili Therapeutics.
Co-founder, President and Head of Investment Banking
Investment Banking
Co-founder who leads investment banking, advising boards, management teams and investors on financings, M&A and partnering deals. Before Bloom Burton he was Head of Healthcare & Biotechnology Investment Banking at an independent dealer; earlier he worked at Export Development Canada and Global Affairs Canada, then in investment banking in Montreal. Honours BA in Applied Studies (Economics) from the University of Waterloo.
Managing Director and Head of Equity Research
Equity Research
Heads equity research, covering public healthcare and emerging biotech companies. He previously led healthcare equity research at a large Canadian independent dealer and was VP Corporate Development and Investor Relations at a medical device company. Holds a PhD in Biochemistry from Western and an MBA from Ivey.
Photo: bloomburton.com (official) (opens in a new tab)
Senior Advisor (partner and board member)
Scientific, regulatory and medical affairs
Partner, senior advisor and board member who serves as the firm's most senior advisor on scientific, regulatory and medical matters for incubated companies and clients. He recently served on active duty in the U.S. Army as Deputy Director of the Office of Regulated Activities, overseeing FDA clinical trials and regulatory filings.
Photo: bloomburton.com (official) (opens in a new tab)
Principal
Investment Banking
Investment banking Principal since 2016, focused on M&A, equity and debt raising and capital markets strategy for healthcare issuers. He previously headed North American institutional equity sales at GMP Securities and institutional sales at Orion Securities. Chairs Grey Wolf Animal Health; HBA from Ivey and CFA charterholder.
Professional information only, drawn from official biographies and published reporting. BSO never lists private contact details.
Sep 15, 2026
Apotex Health Corp.
Underwriter (syndicate member) · Pharmaceuticals
Seller Affiliate of SK Capital Partners; API Investment LP (Sherfam); Allan Oberman
Upsized bought-deal secondary offering of 25,000,000 Apotex Health shares at $34.00 by selling shareholders, for gross proceeds of $850 million; Apotex received no proceeds. RBC Capital Markets, TD Securities and Scotiabank were joint lead bookrunners, and Bloom Burton Securities was one of the syndicate underwriters. The date shown as announced is the prospectus supplement date.
Sep 11, 2026
BetterLife Pharma Inc.
Lead agent · Biotechnology
Vancouver-based BetterLife Pharma (CSE: BETR) closed a US$100 million public offering of common shares and pre-funded warrants on a commercially reasonable efforts agency basis; the date shown as announced is the agency agreement date. Haywood Securities was co-agent.
Jun 30, 2026
Andone Pharmaceuticals Inc.
Exclusive financial advisor to Andone · Pharmaceuticals / Medical Devices / Veterinary
Buyer SteriMax Inc.
SteriMax acquired Andone, an Oakville, Ontario pharmaceutical and medical device company,, expanding into medical device and veterinary markets. Bourne Partners advised SteriMax.
Jun 24, 2026
Helus Pharma
Lead manager (with Lucid Capital Markets) · Biotechnology
US$50 million underwritten offering of common shares at US$4.85 by Nasdaq- and Cboe Canada-listed Helus Pharma (New York and Toronto). Cantor and Barclays were joint bookrunners.
Apr 2, 2024
Searchlight Pharma Inc.
Financial advisor to Searchlight · Pharmaceuticals
Buyer Apotex Inc.
Apotex agreed to acquire private specialty branded pharmaceutical company Searchlight Pharma to expand beyond generics and biosimilars.
Apr 2, 2024
Appili Therapeutics Inc.
Financial advisor to the Appili board · Biotechnology
Buyer Aditxt, Inc.
Aditxt agreed to acquire Appili for cash and Aditxt shares, about US$0.0561 per Appili share, roughly a 117% premium.
Dec 14, 2023
Ceapro Inc.
Financial advisor to Ceapro · Healthcare / Biotech
Buyer Aeterna Zentaris Inc.
Aeterna Zentaris and Ceapro agreed to a merger of equals to create a diversified biopharmaceutical company.
Apr 28, 2022
Field Trip Health Ltd.
Financial advisor to Field Trip; fairness opinion to the board and special committee · Healthcare (Psychedelics)
Field Trip announced a plan of arrangement to separate its Discovery and Health divisions into two independent public companies.
Dec 2020
MindBeacon Holdings Inc.
Underwriter · Healthcare / Digital Health
MindBeacon completed its initial public offering, in which it and selling shareholders including TELUS sold 9.34 million common shares at $8.00 for gross proceeds of about $74.75 million.
Jun 16, 2016
Response Biomedical Corp.
Exclusive financial advisor to Response; fairness opinion and formal valuation to the special committee · Healthcare
Response Biomedical entered agreements for a going-private transaction and concurrent private placement, supported by a fairness opinion and formal valuation for the special committee.
Feb 23, 2012
YM BioSciences Inc.
Financial advisor to YM · Healthcare & Life Sciences
YM BioSciences completed an underwritten public offering of 40.25 million shares at US$2.00, including the over-allotment, for gross proceeds of US$80.5 million.
Bloom Burton honoured Xenon Pharmaceuticals' CEO for a year that included phase 3 results, an FDA filing and a record Canadian biotech equity raise.
The firm marked its 15th anniversary in 2023 and received an Ecosystem Builder Award from BIOTECanada.
Brian Bloom and Jolyon Burton co-founded the firm in 2008 (only the year is published).
No sourced people moves for this firm. BSO publishes a fact only once it can attribute it to a named source, so these stay off the page rather than being filled in from inference. If you know something published that belongs here, it is the fastest way to get it added.
Tell us what we’re missing29
0
1
0
Bloom Burton & Co. · Sep 29, 2026 · bloomburton.com
Apotex Health (reposted by Bloom Burton) · Sep 18, 2026 · bloomburton.com
BetterLife Pharma (reposted by Bloom Burton) · Sep 17, 2026 · bloomburton.com
SteriMax (reposted by Bloom Burton) · Jun 30, 2026 · bloomburton.com
Helus Pharma (reposted by Bloom Burton) · Jun 24, 2026 · bloomburton.com
Bloom Burton & Co. (via Canada Newswire) · Apr 16, 2024 · newswire.ca
Apotex Inc. via CNW · Apr 2, 2024 · newswire.ca
Appili Therapeutics Inc. via GlobeNewswire · Apr 2, 2024 · globenewswire.com
Aeterna Zentaris Inc. (SEC EDGAR exhibit) · Dec 14, 2023 · sec.gov
Field Trip Health (SEC 6-K) · Apr 28, 2022 · sec.gov
MindBeacon Holdings Inc. via GlobeNewswire · Dec 23, 2020 · globenewswire.com
Response Biomedical via SEC EDGAR (8-K Ex. 99.1) · Jun 16, 2016 · sec.gov
YM BioSciences Inc. 6-K via SEC EDGAR · Mar 2, 2012 · sec.gov
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bloom Burton & Co. · Date unavailable · bloomburton.com
Bay Street Oracle · Oct 8, 2026 · intelligence.baystreetoracle.ca
Showing sources for the free preview. 0 further sources support the locked intelligence on this page.
Add your resume and BSO shows how you match Bloom Burton & Co. and the signals in your favour. BSO Pro adds how to position yourself, who to contact and the roles open at your level.
Get your planHave an upcoming interview with Bloom Burton & Co.?
How each round tends to run, what it keeps testing and where candidates lose it, from people who have sat it. Leave your name and we’ll reach out.
Summer 2027
Apply now
Posting open Sep to Oct; Interviews Nov; Offers Dec.Fall 2027
Apply from May 2027
Posting open May to Jun; Interviews Jun to Jul; Offers Jul to Aug.Programs
Summer Analyst · Canada
The independents recruit on their own campus cycles rather than a common one, and the spread is wide: some post in the autumn for the summer after next, while others close as late as the end of January. Postings often sit on school career boards rather than a public careers page, so check both. BSO has not confirmed a timetable for Bloom Burton & Co. on an official page: this records that the intake exists and what the category's cycle looks like, not a published date. Confirm with the firm before you plan around it.
Co-op / Off-cycle intern · Canada
Fall and winter terms are a real route in at this size — the classes are smaller than the summer one and the competition is thinner, and a good off-cycle term usually converts. BSO has not confirmed a timetable for Bloom Burton & Co. on an official page: this records that the intake exists and what the category's cycle looks like, not a published date. Confirm with the firm before you plan around it.
Typical background
GuidanceOne prior internship: a small PE fund, a small investment bank, or corporate development.
Global bulge brackets and elite boutiques
Global banks
Big Six banks
Rising boutiques and mid-market independents
Bloom Burton & Co. is hereBoutiques, small-cap dealers and deal advisory
Where people go next
Guidance